Abstract: Blockchain global positioning system (GPS) devices and methods are provided. A blockchain GPS device includes: a GPS module configured to receive a GPS signal to determine a location of the device, a blockchain interface module configured to facilitate communication between the GPS module and at least one blockchain network, a transaction trigger module configured to initiate a transaction based on a trigger condition, a security protocol module configured to provide secure communication between the GPS module and the at least one blockchain network, and an integration module configured to provide communication integration for the device with the GPS module and the at least one blockchain network.

Abstract: Disclosed herein, in certain embodiments, are anti-hCCR8 antibodies, anti-hCCR8 antibody conjugates, and pharmaceutical compositions which comprise the anti-hCCR8 antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-hCCR8 antibody described herein, and methods of treatment with use of an anti-hCCR8 antibody described herein.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: This disclosure relates to LPA antagonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: Examples described herein relate to a securing sub-system. The securing sub-system includes a lever and a cam assembly engaged with the lever. The cam assembly is movable due to a pivotal movement of the lever and includes a cam body, a cantilevered arm, and a load support member. The cantilevered arm extends from the cam body and is deformable when the cantilevered arm contacts a restrictive structure. The load support member disposed on the insertion cam. A portion of the load support member is offset from an open end of the cantilevered arm to limit deformation of the cantilevered arm. Further, some examples described herein relate to a securing system including a plurality of securing sub-systems coupled via a synchronous movement link is also presented. Moreover, certain examples described herein relate to a computing system including at least one such securing sub-system.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor, gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: Examples described herein relate to a securing sub-system. The securing sub-system includes a lever and a cam assembly engaged with the lever. The cam assembly is movable due to a pivotal movement of the lever and includes a cam body, a cantilevered arm, and a load support member. The cantilevered arm extends from the cam body and is deformable when the cantilevered arm contacts a restrictive structure. The load support member disposed on the insertion cam. A portion of the load support member is offset from an open end of the cantilevered arm to limit deformation of the cantilevered arm. Further, some examples described herein relate to a securing system including a plurality of securing sub-systems coupled via a synchronous movement link is also presented. Moreover, certain examples described herein relate to a computing system including at least one such securing sub-system.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.

Abstract: Methods and systems for removing impurities from a molten salt stream are provided. A molten salt stream is provided that comprises a mixture of compounds selected from the group consisting of LiF, BeF2, and NaF, and ZrF4. The molten salt stream is flowed through a loop that may contain a precipitation filter, electrochemical potential, and/or a sparger, which thereby remove impurities in the molten salt stream. Various physical methods and apparatus are used to control the ability to remove impurities from the molten salt stream based on temperature, solubility, and general chemistry control.

Abstract: A set of search results associated with a query is received, the set of search results including for each of search result in at least a subset of the set an indication of an evidence based at least in part on which the search result was included in the set of search results. A search result display interface is generated in which at least a displayed subset of search results are displayed, the search result display interface include for each of at least a subset of the displayed search results an indication of the corresponding evidence based on which that search result was included in the set of search results.

Abstract: A flameless heater includes a diesel engine, a hydraulic or electric load that is powered by the diesel engine thereby generating heat, a heat exchanger that transfers heat to air flowing through the air from the flameless heat source, and possibly other heat exchangers for heating the air flowing therethrough with engine coolant and/or with exhaust gases. The system may be operated to maintain relatively high load on the engine for at least the majority of the time so as to reduce or negate the need for parked regeneration. The system may also control airflow through the system and possibly other system parameters to obtain a given setpoint such as a given discharge air temperature. In one embodiment, airflow through the system is controlled by louvers under the power of an electric motor or other actuator controlled by the system's controller.

Abstract: A modular panel system including a plurality of posts where each post includes a front face, a rear face, and opposed lateral faces. A central channel is formed in the front face where the central channel has a linking opening, a first ledge and a second ledge. Cutouts are formed in the ledges. The rear face includes a panel receiving channel that receives an edge of a panel. A linking element is configured to be secured in the linking opening. The head of the linking element is sized to fit within the first and the second cutouts and be secured by the first and second ledges to couple the first post to the second post. The lateral faces of the coupled posts together form a first side central channel and a first side central channel cutout that is configured to receive a second linking element to couple a third post to the coupled first and second posts.

Abstract: A set of search results associated with a query is received, the set of search results including for each of search result in at least a subset of the set an indication of an evidence based at least in part on which the search result was included in the set of search results. A search result display interface is generated in which at least a displayed subset of search results are displayed, the search result display interface include for each of at least a subset of the displayed search results an indication of the corresponding evidence based on which that search result was included in the set of search results.

Abstract: A user statement associated with a query is received. The user statement is parsed to determine a set of interpretations matching the user statement. Based at least in part on the set of interpretations the query is determined to be a candidate for iterative improvement. The query is iteratively improved at least in part by prompting a user associated with the user statement to provide a further input.

Abstract: A user statement associated with a natural query is received. A syntactic parse of the user statement is performed to generate a parsed user statement. The parsed user statement is matched against a set of one or more interpretations determined to have meaning in a context of a knowledge base with which the user statement is associated. A user intent is determined based at least in part on said one or more interpretations. A determined query is performed based on said user intent.

Abstract: The instant disclosure relates to an apparatus, system and methods for determining the impact attenuation or hardness of a surface for a playground or sports field in order to mitigate or reduce sports and playground related injuries.